المؤلفون: M. V. Zamergrad, V. A. Parfenov, A. S. Agafina, N. V. Lyamina, M. M. Gavrik, L. R. Kuchumova, E. R. Barantsevich, V. S. Krasnov, A. A. Ivanova, A. L. Vladykin, K. А. Ishchenko, М. В. Замерград, В. А. Парфенов, А. С. Агафьина, Н. В. Лямина, М. М. Гаврик, Л. Р. Кучумова, Е. Р. Баранцевич, В. С. Краснов, А. А. Иванова, А. Л. Владыкин, К. А. Ищенко

المساهمون: This article has been supported by Valenta Pharm, Статья спонсируется компанией «Валента Фарм»

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 15, No 5 (2023); 20-34 ; Неврология, нейропсихиатрия, психосоматика; Vol 15, No 5 (2023); 20-34 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2023-5

مصطلحات موضوعية: клиническое исследование, functional dizziness, persistent postural-perceptual dizziness, chronic subjective dizziness, phobic postural vertigo, buspirone, Vespireit®, prolonged-release tablets, clinical trial, функциональное головокружение, персистирующее постурально-перцептивное головокружение, хроническое субъективное головокружение, постуральная фобическая неустойчивость, буспирон, Веспирейт®, таблетки с пролонгированным высвобождением

وصف الملف: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/2101/1581; Dieterich M, Staab JP, Brandt T. Functional (psychogenic) dizziness. Handb Clin Neurol. 2016;139:447-68. doi:10.1016/B978-0-12801772-2.00037-0; Obermann M, Bock E, Sabev N, et al. Long-term outcome of vertigo and dizziness associated disorders following treatment in specialized tertiary care: the Dizziness and Vertigo Registry (DiVeR) Study. J Neurol. 2015 Sep;262(9):2083-91. doi:10.1007/s00415-015-7803-7. Epub 2015 Jun 20.; Brandt T, Dieterich M, Strupp M. Vertigo and dizziness: common complaints. 2nd ed. London: Springer-Verlag; 2013.; Stone J. Persistent posturo-perceptual dizziness (PPPD) (functional dizziness). 2016. Available from: https://www.neurosymptoms.org/wpcontent/uploads/2020/11/Dizziness-PPPDinformation-sheet-v2.pdf; Bittar RS, Lins EM. Clinical characteristics of patients with persistent postural-perceptual dizziness. Braz J Otorhinolaryngol. 2015 MayJun;81(3):276-82. doi:10.1016/j.bjorl.2014.08.012. Epub 2014 Sep 6.; Holle D, Schulte-Steinberg B, Wurthmann S, et al. Persistent PosturalPerceptual Dizziness: A Matter of Higher, Central Dysfunction? PLoS One. 2015 Nov 16;10(11):e0142468. doi:10.1371/journal.pone.0142468; Webster KE, Harrington-Benton NA, Judd O, et al. Pharmacological interventions for persistent postural-perceptual dizziness (PPPD). Cochrane Database Syst Rev. 2023 Mar 9;3(3):CD015188. doi:10.1002/14651858.CD015188.pub2; Staab JP, Ruckenstein MJ, Solomon D, Shepard NT. Serotonin reuptake inhibitors for dizziness with psychiatric symptoms. Arch Otolaryngol Head Neck Surg. 2002 May;128(5):554-60. doi:10.1001/archotol.128.5.554; Staab JP, Ruckenstein MJ, Amsterdam JD. A prospective trial of sertraline for chronic subjective dizziness. Laryngoscope. 2004 Sep;114(9):1637-41. doi:10.1097/00005537200409000-00025; Horii A, Mitani K, Kitahara T, et al. Paroxetine, a selective serotonin reuptake inhibitor, reduces depressive symptoms and subjective handicaps in patients with dizziness. Otol Neurotol. 2004 Jul;25(4):536-43. doi:10.1097/00129492-200407000-00022; Horii A, Uno A, Kitahara T, et al. Effects of fluvoxamine on anxiety, depression, and subjective handicaps of chronic dizziness patients with or without neuro-otologic diseases. J Vestib Res. 2007;17(1):1-8.; Simon NM, Parker SW, Wernick-Robinson M, et al. Fluoxetine for vestibular dysfunction and anxiety: a prospective pilot study. Psychosomatics. 2005 Jul-Aug;46(4):334-9. doi:10.1176/appi.psy.46.4.334; Colombo B, Teggi R, editors. Vestibular migraine and related syndromes. Springer; 2014.; Babu S, Schutt ChA, Bojrab DI, editors. Diagnosis and treatment of vestibular disorders. Springer; 2019.; Gold D. Neuro-ophthalmology and neuro-otology. A Case-Based Guide for Clinicians and Scientists. Springer; 2022.; Soto E, Vega R, Sesena E. Neuropharmacological basis of vestibular system disorder treatment. J Vestib Res. 2013;23(3):119-37. doi:10.3233/VES-130494; Han L, Wu KL, Kwan PY, et al. 5-HT1A receptor-mediated attenuation of synaptic transmission in rat medial vestibular nucleus impacts on vestibular-related motor function. J Physiol. 2021 Jan;599(1):253-67. doi:10.1113/JP282313; Marcus DA, Furman JM. Prevention of motion sickness with rizatriptan: a doubleblind, placebo-controlled pilot study. Med Sci Monit. 2006 Jan;12(1):PI1-7. Epub 2005 Dec 19.; Jajoo HK, Mayol RF, LaBudde JA, Blair IA. Metabolism of the antianxiety drug buspirone in human subjects. Drug Metab Dispos. 1989 Nov-Dec;17(6):634-40.; Goa KL, Ward A. Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs. 1986 Aug;32(2):114-29. doi:10.2165/00003495198632020-00002; Riblet LA, Eison AS, Eison MS, et al. Neuropharmacology of buspirone. Psychopathology. 1984;17 Suppl 3:69-78. doi:10.1159/000284133; Product monograph – Buspirone (buspirone hydrochloride tablets, USP, 5 mg and 10 mg). Pharmascience Inc.; 2016.; Sakr A, Andheria M. Pharmacokinetics of buspirone extended-release tablets: a singledose study. J Clin Pharmacol. 2001 Jul;41(7):783-9. doi:10.1177/00912700122010582; Study report: a randomized, open label, three-treatment, three-period, three-sequence, crossover, pilot, comparative bioavailability study of buspirone 15 mg sustained release tablets [two different formulations – VPH016100 and VPH016101] of JSC Valenta Pharmaceuticals, Russia and three tablets of Buspin tablet [buspirone] 5 mg of Intas Pharmaceuticals, India, in healthy adult subjects under fasting condition. Version No.: 6.0, Date: 16-Dec-2015.; Открытое, трехэтапное исследование переносимости, безопасности и фармакокинетических параметров препарата Буспирон, таблетки с пролонгированным высвобождением, 15 мг (АО «Валента Фарм», Россия) при однократном применении с изучением фактора приема пищи и многократном применении у здоровых добровольцев. Отчет о клиническом исследовании. Тбилиси; 2019.; Loane C, Politis M. Buspirone: what is it all about? Brain Res. 2012 Jun 21;1461:111-8. doi:10.1016/j.brainres.2012.04.032. Epub 2012 Apr 24.; Newman-Tancredi A, Gavaudan S, Conte C, et al. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol. 1998 Aug 21;355(2-3):245-56. doi:10.1016/s0014-2999(98)00483-x; Tunnicliff G. Molecular basis of buspirone's anxiolytic action. Pharmacol Toxicol. 1991 Sep;69(3):149-56. doi:10.1111/j.16000773.1991.tb01289.x; Buspirone [Electronic resource]. DrugBank. Available from: https://www.drugbank.ca/drugs/DB00490 (accessed 01.05.2019).; Carli M, Prontera C, Samanin R. Evidence that central 5-hydroxytryptaminergic neurones are involved in the anxiolytic activity of buspirone. Br J Pharmacol. 1989 Apr;96(4):829-36. doi:10.1111/j.14765381.1989.tb11891.x; Adell A, Sarna GS, Hutson PH, Curzon G. An in vivo dialysis and behavioural study of the release of 5-HT by p-chloroamphetamine in reserpine-treated rats. Br J Pharmacol. 1989 May;97(1):206-12. doi:10.1111/j.14765381.1989.tb11943.x; Sharp T, Bramwell SR, Grahame-Smith DG. 5-HT1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br J Pharmacol. 1989 Feb;96(2):283-90. doi:10.1111/j.14765381.1989.tb11815.x; Sprouse JS, Aghajanian GK. Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists. Synapse. 1987;1(1):3-9. doi:10.1002/syn.890010103; Sillar KT, Simmers AJ. Presynaptic inhibition of primary afferent transmitter release by 5-hydroxytryptamine at a mechanosensory synapse in the vertebrate spinal cord. J Neurosci. 1994 May;14(5 Pt 1):2636-47. doi:10.1523/JNEUROSCI.14-05-02636.1994; McNaughton N, Panickar KS, Logan B. The pituitary-adrenal axis and the different behavioral effects of buspirone and chlordiazepoxide. Pharmacol Biochem Behav. 1996 May;54(1):51-6. doi:10.1016/00913057(95)02129-9; Hodges H, Green S, Glenn B. Evidence that the amygdala is involved in benzodiazepine and serotonergic effects on punished responding but not on discrimination. Psychopharmacology (Berl). 1987;92(4):491-504. doi:10.1007/BF00176484; Drescher MJ, Cho WJ, Folbe AJ, et al. An adenylyl cyclase signaling pathway predicts direct dopaminergic input to vestibular hair cells. Neuroscience. 2010 Dec 29;171(4):105474. doi:10.1016/j.neuroscience.2010.09.051. Epub 2010 Sep 29.; Gallagher JP, Phelan KD, Shinnick-Gallagher P. Modulation of excitatory transmission at the rat medial vestibular nucleus synapse. Ann N Y Acad Sci. 1992 May 22;656:630-44. doi:10.1111/j.17496632.1992.tb25241.x; Andrianov GN, Ryzhova IV, Tobias TV. Dopaminergic modulation of afferent synaptic transmission in the semicircular canals of frogs. Neurosignals. 2009;17(3):222-8. doi:10.1159/000224632. Epub 2009 Jun 17.; New JS. The discovery and development of buspirone: a new approach to the treatment of anxiety. Med Res Rev. 1990 JulSep;10(3):283-326. doi:10.1002/med.2610100302; Rang HP, Dale MM, Ritter JM, Flower RJ. Pharmacology. 6th ed. Churchill Livingstone; 2008.; Проспективное двухэтапное мультицентровое рандомизированное двойное слепое плацебо-контролируемое исследование в параллельных группах по оценке эффективности, безопасности и переносимости лекарственного препарата Буспирон, таблетки с пролонгированным высвобождением, 15 мг (АО «Валента Фарм», Россия), при его применении у пациентов с синдромом вегетативной дисфункции, сопровождающимся головокружением. Протокол исследования № БУСП-02-02-2019. Отчет о клиническом исследовании II фазы. 21.01.2020.; Двойное слепое плацебо-контролируемое многоцентровое рандомизированное клиническое исследование по оценке эффективности и безопасности применения препарата Буспирон, таблетки с пролонгированным высвобождением, 15 мг (АО «Валента Фарм», Россия) у пациентов с синдромом вегетативной дисфункции, сопровождающимся головокружением. Протокол исследования БУСП-03-03-2021. Отчет о клиническом исследовании 2022 г.; Koppelaar-van Eijsden HM, Schermer TR, Bruintjes TD. Measurement Properties of the Dizziness Handicap Inventory: A Systematic Review. Otol Neurotol. 2022 Mar 1;43(3):e282-e297. doi:10.1097/MAO.0000000000003448; Available from: https://clinicaltrials.gov/ct2/show/NCT05430217?term=buspirone&cond=buspirone&cntry=RU&draw=2&rank=1; ICD-11 for Mortality and Morbidity Statistics (Version: 02/2022). Available from: https://icd.who.int/browse11/lm/en#/http%3a%2f%2fid.who.int%2ficd%2fentity%2f579898286; Rocco PL, Giavedoni A, Pacella G. Withdrawal from benzodiazepines in a hospital setting: An open trial with buspirone. Curr Ther Res. 1992;52(3):386-9.; Feighner JP, Cohn JB. Analysis of individual symptoms in generalized anxiety – a pooled, multistudy, double-blind evaluation of buspirone. Neuropsychobiology. 1989;21(3):124-30. doi:10.1159/000118565; Sramek JJ, Tansman M, Suri A, et al. Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. J Clin Psychiatry. 1996 Jul;57(7):287-91.; Fulton B, Brogden RN. Buspirone. CNS Drugs. 1997;7(1):68-88.; Laakmann G, Schüle C, Lorkowski G, et al. Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacology (Berl). 1998 Apr;136(4):357-66. doi:10.1007/s002130050578; Apter JT, Allen LA. Buspirone: future directions. J Clin Psychopharmacol. 1999 Feb;19(1):86-93. doi:10.1097/00004714199902000-00014; Flint AJ. Generalised anxiety disorder in elderly patients: epidemiology, diagnosis and treatment options. Drugs Aging. 2005;22(2):101-14. doi:10.2165/00002512200522020-00002; Gale CK, Millichamp J. Generalised anxiety disorder in children and adolescents. BMJ Clin Evid. 2016 Jan 13;2016:1002.; BuSpar® (Bristol-Myers Squibb Company, USA). U.S. Food and Drug Administration (FDA). Drug label, revised November 2010. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018731s051lbl.pdf; Инструкция по медицинскому применению лекарственного препарата Спитомин® таблетки 5 мг и 10 мг.; https://nnp.ima-press.net/nnp/article/view/2101

الاتاحة: https://nnp.ima-press.net/nnp/article/view/2101
https://doi.org/10.14412/2074-2711-2023-5-20-34

المؤلفون: O. D. Ostroumova, M. L. Maksimov, M. V. Zamergrad, V. A. Parfenov, E. K. Zaharova, A. L. Vladykin, A. A. Globenko, A. V. Kapashin, K. A. Ishchenko, О. Д. Остроумова, М. Л. Максимов, М. В. Замерград, В. А. Парфенов, Е. К. Захарова, А. Л. Владыкин, А. А. Глобенко, А. В. Капашин, К. А. Ищенко

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 15, No 4 (2023); 53-65 ; Неврология, нейропсихиатрия, психосоматика; Vol 15, No 4 (2023); 53-65 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2023-4

مصطلحات موضوعية: безопасность, pharmacokinetics, 6-hydroxybuspirone, 1-(2-pyrimidinyl)-piperazine, prolonged-release tablets, tolerability, safety, фармакокинетика, 6-гидроксибуспирон, 1-(2-пиримидинил)-пиперазин, таблетки с пролонгированным высвобождением, переносимость

وصف الملف: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/2060/1558; Gammans RE, Westrick ML, Shea JP, et al. Pharmacokinetics of buspirone in elderly subjects. J Clin Pharmacol. 1989 Jan;29(1):72-8. doi:10.1002/j.1552-4604.1989.tb03240.x; Mezher AW, McKnight CA, Caplan JP. Buspirone Abuse: No Safe Haven. Psychosomatics. 2019 Sep-Oct;60(5):534-35. doi:10.1016/j.psym.2018.12.008. Epub 2018 Dec 23.; Temple DL Jr, Yevich JP, New JS. Buspirone: chemical profile of a new class of anxioselective agents. J Clin Psychiatry. 1982 Dec;43(12 Pt 2):4-10.; Jones BDM, Husain MI. Tranquilizer/ Anxiolytics: Buspirone. In: Riederer P, Laux G, Nagatsu T, Le W, Riederer C (eds). NeuroPsychopharmacotherapy. Springer, Cham; 2021. doi:10.1007/978-3-319-56015-1_160-1; Sramek JJ, Hong WW, Hamid S, et al. Meta-analysis of the safety and tolerability of two dose regimens of buspirone in patients with persistent anxiety. Depress Anxiety. 1999;9(3):131-4.; Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues Clin Neurosci. 2017 Jun;19(2):93-107. doi:10.31887/DCNS.2017.19.2/bbandelow; Jajoo HK, Mayol RF, LaBudde JA, Blair IA. Metabolism of the antianxiety drug buspirone in human subjects. Drug Metab Dispos. 1989 Nov-Dec;17(6):634-40.; Norman S. The uses of buspirone in psychiatry. J Clin Psychiatry. 1994;12(1):3-10.; Garakani A, Murrough JW, Freire RC, et al. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Front Psychiatry. 2020 Dec 23;11:595584. doi:10.3389/fpsyt.2020.595584; Mayol RF, Adamson DS, Gammans RE,LaBudde JA. Pharmacokinetics and disposition of 14C-buspirone HCl after intravenous and oral dosing in man. Clin Pharmacol Ther. 1985;37:210.; Loane C, Politis M. Buspirone: what is it allabout? Brain Res. 2012 Jun 21;1461:111-8. doi:10.1016/j.brainres.2012.04.032. Epub 2012 Apr 24.; Caccia S, Vigano GL, Mingardi G, et al.Clinical pharmacokinetics of oral buspirone in patients with impaired renal function. Clin Pharmacokinet. 1988 Mar;14(3):171-7. doi:10.2165/00003088-198814030-00005; Gammans RE, Mayol RF, LaBudde JA.Metabolism and disposition of buspirone. Am J Med. 1986 Mar 31;80(3B):41-51. doi:10.1016/0002-9343(86)90331-1; Physician’s Desk Reference. 45th ed. Montvale, NJ: Medical Economics Company; 1991.; Caccia S, Conti I, Vigano G, Garattini S.1-(2-Pyrimidinyl)-piperazine as active metabolite of buspirone in man and rat. Pharmacology. 1986;33(1):46-51. doi:10.1159/000138199; Bianchi G, Garattini S. Blockade of alpha2-adrenoceptors by 1-(2-pyrimidinyl)-piperazine (PmP) in vivo and its relation to the activity of buspirone. Eur J Pharmacol. 1988 Mar 15;147(3):343-50. doi:10.1016/0014-2999(88)90167-7; Sakr A, Andheria M. Pharmacokinetics of buspirone extended-release tablets: a single-dose study. J Clin Pharmacol. 2001 Jul;41(7):783-9. doi:10.1177/00912700122010582; Sakr A, Andheria M. A comparative multidose pharmacokinetic study of buspirone extended-release tablets with a reference immediate-release product. J Clin Pharmacol. 2001 Aug;41(8):886-94. doi:10.1177/00912700122010681; Открытое, трехэтапное исследование переносимости, безопасности и фармакокинетических параметров препарата Буспирон, таблетки с пролонгированным высвобождением, 15 мг (АО «Валента Фарм», Россия) при однократном применении с изучением фактора приема пищи и многократном применении у здоровых добровольцев. Протокол исследования № BUSP-01-01-2018. Отчет о результатах клинического исследования. Версия от 18.06.2019.; US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: “Food-effect bioavailability and fed bioequivalence studies”. Rockville, MD: U.S. Food and Drug Administration; 2002.; BuSpar® (Bristol-Myers Squibb Company, USA). U.S. Food and Drug Administration (FDA). Drug label, revised November 2010. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018731s051lbl.pdf (accessed 01.09.2018).; Goa KL, Ward A. Buspirone. A preliminaryreview of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs. 1986 Aug;32(2):114-29. doi:10.2165/00003495198632020-00002; Study report: a randomized, open label,three-treatment, three-period, three-sequence, crossover, pilot, comparative bioavailability study of buspirone 15 mg sustained release tablets [two different formulations – VPH016100 and VPH016101] of JSC Valenta Pharmaceuticals, Russia and three tablets of Buspin tablet [buspirone] 5 mg of Intas Pharmaceuticals, India, in healthy adult subjects under fasting condition. Version No.: 6.0, Date: 16-Dec-2015.; Goldberg HL, Finnerty R. Comparison of buspirone in two separate studies. J Clin Psychiatry. 1982 Dec;43(12 Pt 2):87-91.; Gammans RE, Mayol RF, Mackenthun AV,Sokya LF. The relationship between buspirone bioavailability and dose in healthy subjects. Biopharm Drug Dispos. 1985 Apr-Jun;6(2):139-45. doi:10.1002/bdd.2510060205; Проспективное двухэтапное мультицентровое рандомизированное двойное слепое плацебо-контролируемое исследование в параллельных группах по оценке эффективности, безопасности, переносимости и фармакокинетики лекарственного препарата Буспирон, таблетки с пролонгированным высвобождением, 15 мг (АО «Валента Фарм», Россия), при его применении у пациентов с синдромом вегетативной дисфункции, сопровождающимся головокружением. Протокол исследования № БУСП-02-02-2019. Отчет о клиническом исследовании 21.01.2020.; Mahmood I, Sahajwalla C. Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. Clin Pharmacokinet. 1999 Apr;36(4):277-87. doi:10.2165/00003088199936040-00003; Product monograph – Buspirone (buspirone hydrochloride tablets, USP, 5 mg and 10 mg). Pharmascience Inc.; 2016.; Инструкции по медицинскому применению лекарственного препарата Спитомин®, таблетки 5 мг и 10 мг.; https://nnp.ima-press.net/nnp/article/view/2060

الاتاحة: https://nnp.ima-press.net/nnp/article/view/2060
https://doi.org/10.14412/2074-2711-2023-4-53-65

المؤلفون: Ju. E. Azimova, Yu. P. Sivolap, K. A. Ishchenko, Ю. Э. Азимова, Ю. П. Сиволап, К. А. Ищенко

المساهمون: This article has been supported by Valenta Pharm, Статья спонсируется компанией «Валента Фарм».

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 15, No 3 (2023); 68-75 ; Неврология, нейропсихиатрия, психосоматика; Vol 15, No 3 (2023); 68-75 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2023-3

مصطلحات موضوعية: безопасность, prolonged release, Teraligen® retard, generalized anxiety disorder, effectiveness, safety, Тералиджен® ретард, пролонгированная форма, генерализованное тревожное расстройство, эффективность

وصف الملف: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/2032/1538; Szuhany KL, Simon NM. Anxiety Disorders: A Review. JAMA. 2022 Dec 27;328(24):2431-45. doi:10.1001/jama.2022.22744; DeMartini J, Patel G, Fancher TL. Generalized Anxiety Disorder. Ann Intern Med. 2019 Apr 2;170(7):ITC49-ITC64. doi:10.7326/AITC201904020; Bandelow B. Current and Novel Psychopharmacological Drugs for Anxiety Disorders. Adv Exp Med Biol. 2020;1191:34765. doi:10.1007/978-981-32-9705-0_19; Maneeton N, Maneeton B, Woottiluk P, et al. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2016 Jan 12;10:259-76. doi:10.2147/DDDT.S89485; Schatzberg A, DeBattista C. Schatzberg’s Manual of Clinical Psychopharmacology. 9th ed. Washington: American Psychiatric Association Publishing; 2019. 811 p.; Barantsevich ER, Golovkova MS, Dzhulaj IA, et al. The efficacy and safety of teraligen in patients with brain ischemia, stages I and II, and psychoautonomic syndrome. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2015;115(12):86-91. doi:10.17116/jnevro201511511286-91 (In Russ.).; Reykhart DV, Arnautov VS, Globenko AA, et al. Single dose bioavailability and pharmacokinetic parameters of Teraligen® retard and Teraligen® Valenta tablets in healthy volunteers. Khimiko-farmatsevticheskiy zhurnal. 2017;51(8):25-30. doi:10.30906/0023-11342017-51-8-25-30 (In Russ.).; https://nnp.ima-press.net/nnp/article/view/2032

الاتاحة: https://nnp.ima-press.net/nnp/article/view/2032
https://doi.org/10.14412/2074-2711-2023-3-68-75